References: Nonresponse to initial pharmacotherapy for posttraumatic stress disorder in adults and young people

Albert U, Carmassi C, Cosci F, De Cori D, Di Nicola M, Ferrari S, et al. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Int Clin Psychopharmacol 2016;31(5):249–58. https://www.ncbi.nlm.nih.gov/pubmed/26974213
Australian Government Department of Health and Aged Care. MDMA and psilocybin hub. Woden, ACT: Therapeutic Goods Administration; November 2024. https://www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybin-hub
Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014;28(5):403–39. https://www.ncbi.nlm.nih.gov/pubmed/24713617
Committee for Evidence-Based Practice and Committee for Research. Therapeutic use of psychedelic substances [Clinical Memorandum]. Melbourne, Victoria: Royal Australian And New Zealand College of Psychiatrists; June 2023. https://www.ranzcp.org/clinical-guidelines-publications/clinical-guidelines-publications-library/therapeutic-use-of-psychedelic-substances
Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014;14 Suppl 1:S1. https://www.ncbi.nlm.nih.gov/pubmed/25081580
Phoenix Australia. Australian guidelines for the prevention and treatment of acute stress disorder, posttraumatic stress disorder and complex PTSD. Melbourne: Phoenix Australia; 2020. https://www.phoenixaustralia.org/australian-guidelines-for-ptsd/
Psychedelic-Assisted Therapy Steering Group. Therapeutic use of MDMA for PTSD and psilocybin for treatment resistant depression [Clinical Memorandum]. Melbourne, Victoria: Royal Australian and New Zealand College of Psychiatrists; 2023. https://www.ranzcp.org/clinical-guidelines-publications/clinical-guidelines-publications-library/therapeutic-use-of-mdma-for-ptsd-and-psilocybin-for-treatment-resistant-depression